Arcutis Biotherapeutics Q3 EPS $(0.73) Beats $(0.86) Estimate, Sales $38.10M Beat $32.83M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics reported Q3 losses of $(0.73) per share, beating the analyst consensus estimate of $(0.86) by 15.12%. This is a 61.38% increase over losses from the same period last year. The company also reported quarterly sales of $38.10 million, beating the analyst consensus estimate of $32.83 million by 16.06%. This is a 5.16K% increase over sales from the same period last year.
November 03, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcutis Biotherapeutics reported better than expected Q3 results, with losses and sales beating analyst estimates.
Arcutis Biotherapeutics reported Q3 results that beat analyst estimates. The company's losses were lower than expected and sales were higher than expected, which is likely to be viewed positively by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100